Literature DB >> 11874840

Influence of HLA polymorphism on persistent remission in rheumatoid arthritis.

E T H Molenaar1, A E Voskuyl, I E van der Horst-Bruinsma, G M Th Schreuder, E Zanelli, B A C Dijkmans.   

Abstract

BACKGROUND: Several studies have reported an association between the presence of the shared epitope (SE) and susceptibility to rheumatoid arthritis (RA). Recent studies have shown that certain HLA-DRB1 alleles in combination with predisposing DQB1 and DQA1 alleles may protect against the development of RA. This model is known as the rheumatoid arthritis protection (RAP) hypothesis.
OBJECTIVE: To determine the distribution of HLA-DRB1 and DQB1/DQA1 alleles in a cohort of patients with RA in remission and to determine the association between these HLA alleles and the persistence of remission. PATIENTS AND METHODS: HLA-DRB1 and DQB1 typings were performed in 167 patients with RA in remission, defined according to the American College of Rheumatology criteria. The disease course, as defined by the persistence of remission during a follow up of two years, was compared between subgroups. According to the RAP hypothesis patients were divided into three subgroups: patients carrying predisposing DQ alleles, patients carrying predisposing alleles in combination with protective alleles (DQ(RA+)/DERAA phenotype), and patients lacking the predisposing alleles. According to the SE hypothesis, patients were divided into three subgroups based on whether they were carrying two, one, or no predisposing alleles (SE alleles).
RESULTS: Predisposing DQ alleles along with a DERAA-bearing allele were present in 14 (8%) of the 167 patients. At least one SE allele was present in 116 (69%) patients; 34 of them (20%) were carrying two copies. The disease course was not significantly different between the subgroups according to the SE and RAP hypothesis, respectively.
CONCLUSION: The frequency of DQ(RA+)/DERAA combinations and of SE alleles in patients with RA clinically in remission was similar to that found in other RA populations. Persistent remission of RA was not associated with any particular HLA subtypes, indicating that HLA typing is not useful for predicting persistent clinical remission.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11874840      PMCID: PMC1754060          DOI: 10.1136/ard.61.4.351

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

1.  A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers.

Authors:  Cristina Pomirleanu; Codrina Ancuta; Smaranda Miu; Rodica Chirieac
Journal:  Clin Rheumatol       Date:  2013-01-06       Impact factor: 2.980

2.  Effect of Anti-Cyclic Citrullinated Peptide and HLA-DRB1 Subtypes on Clinical Disease Activity Index in Rheumatoid Arthritis Patients.

Authors:  Akbar Soleimani; Zahra Mobedi; Maryam Al-E-Rasul; Abolghasem Sharifi; Abdolrahim Kazemi Vardanjani
Journal:  J Clin Diagn Res       Date:  2017-03-01

3.  Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.

Authors:  L Gossec; M Dougados; P Goupille; A Cantagrel; J Sibilia; O Meyer; J Sany; J-P Daurès; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

4.  Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study.

Authors:  M A Quintana-Duque; F Rondon-Herrera; R D Mantilla; E Calvo-Paramo; J J Yunis; A Varela-Nariño; J F Restrepo; A Iglesias-Gamarra
Journal:  Clin Rheumatol       Date:  2016-04-04       Impact factor: 2.980

Review 5.  Induction of remission in rheumatoid arthritis: criteria and opportunities.

Authors:  Guido Valesini; Manuela Di Franco; Francesca Romana Spinelli; Rossana Scrivo
Journal:  Rheumatol Int       Date:  2008-09-21       Impact factor: 3.580

Review 6.  Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Authors:  Vasco Crispim Romão; Helena Canhão; João Eurico Fonseca
Journal:  BMC Med       Date:  2013-01-23       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.